Christian Graham Peace

Christian Graham Peace

Auto-generated profile, based on publicly available information

Christian Graham Peace

School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CPChristian G. Peace
Christian G. Peace
Luke O'NeillLuke O'Neill
Luke O'Neill
Macrophages exposed to inflammatory stimuli including LPS undergo metabolic reprogramming to facilitate macrophage effector function. This metabolic reprogramming supports phagocytic function, cytokine release, and ROS production that are critical to protective inflammatory responses. The Krebs cycle is a central metabolic pathway within all mammalian cell types. In activated macrophages, distinct breaks in the Krebs cycle regulate macrophage effector function through the accumulation of several metabolites that were recently shown to have signaling roles in immunity. One metabolite that accumulates in macrophages because of the disturbance in the Krebs cycle is itaconate, which is derived from cis-aconitate by the enzyme cis-aconitate decarboxylase (ACOD1), encoded by immunoresponsive gene 1 (Irg1). This Review focuses on itaconate’s emergence as a key immunometabolite with diverse roles in immunity and inflammation. These roles include inhibition of succinate dehydrogenase (which controls levels of succinate, a metabolite with multiple roles in inflammation), inhibition of glycolysis at multiple levels (which will limit inflammation), activation of the antiinflammatory transcription factors Nrf2 and ATF3, and inhibition of the NLRP3 inflammasome. Itaconate and its derivatives have antiinflammatory effects in preclinical models of sepsis, viral infections, psoriasis, gout, ischemia/reperfusion injury, and pulmonary fibrosis, pointing to possible itaconate-based therapeutics for a range of inflammatory diseases. This intriguing metabolite continues to yield fascinating insights into the role of metabolic reprogramming in host defense and inflammation.

8 March 2023 in Nature
Verified
Journal Article
Closed access
PDF file
AHAlexander Hooftman
Alexander Hooftman
CPChristian G. Peace
Christian G. Peace
DRDylan G. Ryan
Dylan G. Ryan
EDEmily A. Day
Emily A. Day
MYMing Yang
Ming Yang
Luke O'NeillLuke O'Neill
Luke O'Neill

14 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
TRTristram A. J. Ryan
Tristram A. J. Ryan
AHAlexander Hooftman
Alexander Hooftman
ARAisling M. Rehill
Aisling M. Rehill
Matt JohansenMatt Johansen
Matt Johansen
EBEóin C. O’ Brien
Eóin C. O’ Brien
Luke O'NeillLuke O'Neill
Luke O'Neill
Excessive inflammation-associated coagulation is a feature of infectious diseases, occurring in such conditions as bacterial sepsis and COVID-19. It can lead to disseminated intravascular coagulation, one of the leading causes of mortality worldwide. Recently, type I interferon (IFN) signaling has been shown to be required for tissue factor (TF; gene name F3) release from macrophages, a critical initiator of coagulation, providing an important mechanistic link between innate immunity and coagulation. The mechanism of release involves type I IFN-induced caspase-11 which promotes macrophage pyroptosis. Here we find that F3 is a type I IFN-stimulated gene. Furthermore, F3 induction by lipopolysaccharide (LPS) is inhibited by the anti-inflammatory agents dimethyl fumarate (DMF) and 4-octyl itaconate (4-OI). Mechanistically, inhibition of F3 by DMF and 4-OI involves suppression of Ifnb1 expression. Additionally, they block type I IFN- and caspase-11-mediated macrophage pyroptosis, and subsequent TF release. Thereby, DMF and 4-OI inhibit TF-dependent thrombin generation. In vivo, DMF and 4-OI suppress TF-dependent thrombin generation, pulmonary thromboinflammation, and lethality induced by LPS, E. coli, and S. aureus, with 4-OI additionally attenuating inflammation-associated coagulation in a model of SARS-CoV-2 infection. Our results identify the clinically approved drug DMF and the pre-clinical tool compound 4-OI as anticoagulants that inhibit TF-mediated coagulopathy via inhibition of the macrophage type I IFN-TF axis.

6 November 2023 in Trends in Cell Biology
Verified
Journal Article
Closed access
CPChristian G. Peace
Christian G. Peace
SOShane M. O’cArroll
Shane M. O’cArroll
LOLuke A.J. O’nEill
Luke A.J. O’nEill

23 November 2023 in Journal of Innate Immunity
Verified
Journal Article
Open access
PDF file
DRDylan Gerard Ryan
Dylan Gerard Ryan
CPChristian Graham Peace
Christian Graham Peace
AHAlexander Hooftman
Alexander Hooftman
Background: Innate immune cells play a crucial role in responding to microbial infections, but their improper activation can also drive inflammatory disease. For this reason, their activation state is governed by a multitude of factors, including the metabolic state of the cell and, more specifically, the individual metabolites which accumulate intracellularly and extracellularly. This relationship is bidirectional, as innate immune cell activation by pathogen-associated molecular patterns causes critical changes in cellular metabolism. Summary: In this review, we describe the emergence of various “immunometabolites.” We outline the general characteristics of these immunometabolites, the conditions under which they accumulate, and their subsequent impact on immune cells. We delve into well-studied metabolites of recent years, such as succinate and itaconate, as well as newly emerging immunometabolites, such as methylglyoxal. Key Messages: We hope that this review may be used as a framework for further studies dissecting the mechanisms by which immunometabolites regulate the immune system and provide an outlook to harnessing these mechanisms in the treatment of inflammatory diseases.

5 September 2023 in Clinical and Translational Medicine
Verified
Journal Article
Open access
CPChristian G. Peace
Christian G. Peace
AHAlexander Hooftman
Alexander Hooftman
DRDylan G. Ryan
Dylan G. Ryan